Dow Up0.64% Nasdaq Up0.68%

Halozyme Therapeutics, Inc. (HALO)

-NasdaqGS
9.88 0.00(0.00%) 4:00PM EDT
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingJun 30, 2014Mar 31, 2014Dec 31, 2013Sep 30, 2013
Total Revenue 18,385   11,966   12,499   16,014  
Cost of Revenue5,924  5,520  3,540  683  
Gross Profit 12,461   6,446   8,959   15,331  
Operating Expenses
Research Development18,649  21,415  20,925  25,689  
Selling General and Administrative8,752  10,250  9,357  8,135  
Non Recurring -   -   -   -  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (14,940) (25,219) (21,323) (18,493)
Income from Continuing Operations
Total Other Income/Expenses Net118  47  65  52  
Earnings Before Interest And Taxes(14,822)(25,172)(21,259)(18,442)
Interest Expense1,451  1,376  728  851  
Income Before Tax(16,273)(26,548)(21,986)(19,292)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(16,273)(26,548)(21,986)(19,292)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (16,273) (26,548) (21,986) (19,292)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (16,273) (26,548) (21,986) (19,292)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.